For instance, melanoma patients responding to anti-PD-1 therapy have been shown to exhibit higher microbial diversity and an enrichment of specific bacterial taxa, compared with non-responders, in the gut microbiota (78). The gene discussed is PDCD1; the disease is melanoma.